RxDoctor Payments Data

Robert Martyn, MD

Interventional Cardiology · Loudon, TNNPI 1265422760

Payments from drug & device makers

$10,227in general payments, 2019–2025

Across 433 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Johnson & Johnson$891
  • AstraZeneca$864
  • Amgen$760
  • Penumbra, Inc.$672
  • Medtronic$666
  • plus $5K from 38 others

What the payments were for

  • Travel & lodging$2272%
  • Food & beverage$9,99498%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,227 in reported general payments places this provider in the 55th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$82,784
Medicare patients
551
Services billed
1,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$89,820
XareltoRivaroxaban27$29,428
EntrestoSacubitril/Valsartan20$22,407
FarxigaDapagliflozin Propanediol13$9,944
Repatha SureclickEvolocumab13$9,094
Diltiazem 24hr Er (Cd)Diltiazem Hcl94$1,761
ClopidogrelClopidogrel Bisulfate124$1,075
Flecainide Acetate26$938
Ezetimibe23$794
Carvedilol87$584
Atorvastatin Calcium84$545
SotalolSotalol Hcl25$517
Amiodarone Hcl37$417
Metoprolol Succinate64$394
Chlorthalidone13$346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$225$89,82088 claims
Johnson & JohnsonXarelto$891$29,42827 claims
NovartisEntresto$497$22,40720 claims
AstraZenecaFarxiga$864$9,94413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Loudon

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →